Details for New Drug Application (NDA): 062544
✉ Email this page to a colleague
NDA 062544 describes DEXACIDIN, which is a drug marketed by Novartis and is included in two NDAs. Additional details are available on the DEXACIDIN profile page.
The generic ingredient in DEXACIDIN is dexamethasone; neomycin sulfate; polymyxin b sulfate. There are thirty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the dexamethasone; neomycin sulfate; polymyxin b sulfate profile page.
The generic ingredient in DEXACIDIN is dexamethasone; neomycin sulfate; polymyxin b sulfate. There are thirty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the dexamethasone; neomycin sulfate; polymyxin b sulfate profile page.
Summary for 062544
| Tradename: | DEXACIDIN |
| Applicant: | Novartis |
| Ingredient: | dexamethasone; neomycin sulfate; polymyxin b sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | ||||
| Approval Date: | Oct 29, 1984 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
